



Eden Biodesign eBook

Celebrating
10 Years of Success



THE WATSON GROUP



Eden Biodesign eBook

Chapter 1: Overview

Chapter 2: Our History

Chapter 3: Much More than a CMO

Chapter 4: Key Milestones

Chapter 5: About Eden Biodesign



Eden Biodesign is celebrating **10 years of success**. Join us as we reflect on our history and look ahead toward an even brighter future.





Chapter 1: Overview

This Summer marks the 10 year anniversary of Eden Biodesign. This is a cause for celebration!

As we remain committed to the future – building on our position as a leading, global biopharmaceutical contract services business and recognized biologics centre of excellence – it is fitting to reflect on our past and revisit some of our achievements over the past decade.

Read on to learn about our humble beginnings, commitment to growth and success and our long-standing reputation for being much more than CMO.



Chapter 2: Our History

Eden Biodesign has grown from a single roomed office to a multinational organisation with locations in the United States and Europe as well as partner organisations around the globe. We operate a custom designed, 41,000 sq ft MHRA licensed multi-technology and multi-product cGMP biomanufacturing centre in Liverpool, UK, which employs 90 people and is poised to commence a new round of expansion.

Prior to 2000 and the founding of Eden, our core team worked together at Medeva PLC, gaining pan-European approval for a complex recombinant mammalian vaccine. This experience under-pinned the formation of Eden as a consultancy specialising in CMC strategy and regulatory affairs and ultimately led to Eden Biodesign being selected by the UK government in 2003 to design, build and operate the UK's National Biomanufacturing Centre.



While we've had a major public sector client, Eden has always been a fully private, commercial business. Since 2004, Eden Biodesign has raised over £10m of capital from investors to pursue expansion.

Eden took on the lease of the National Biomanufacturing Centre in 2006 and obtained its cGMP manufacturing license for IMPs in early 2007. The public sector service contract was completed by the end of 2008 with over 200 UK companies and academic groups assisted by Eden.

In January 2010, Eden Biodesign was acquired and is now a wholly-owned subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI). Watson is a global specialty pharmaceutical company with \$3 billion in revenues, a broad product line and operations in well-established and emerging markets. This provides Eden and our customers with extremely strong security as we continue to be dedicated to providing contract services to the marketplace.



Chapter 3: Much More than a CMO

Eden Biodesign still maintains the entrepreneurial spirit, dedication to customer service and unmatched knowledge of development of both biotherapeutic and vaccine products that served it so well in the early years. By “beginning with the end in mind” on every customer project, Eden has developed a reputation for being “much more than a CMO” and has successfully completed assignments for customers on six of the seven continents.

We are a valued partner for organizations ranging from

start-up biotechnology companies to multinational pharmaceutical companies and have also served governments, charities and financial institutions along the way.


Eden Biodesign is unusual in that we offer process development and cGMP manufacturing services for products derived from all three major production platforms: mammalian, microbial and viral. This, in turn, means that we have been able to assist customers with the development of a wide range



of different biological product types, including monoclonal antibodies, recombinant protein therapeutics, gene therapies, prophylactic and therapeutic vaccines and cellular products.

We have direct experience in taking vaccines from concept to commercial licensure, and expertise developed by working with a wide range of vaccine technologies. This know-how, coupled with our flexible, segregated, state of the art facilities makes us an ideal partner for vaccine developers.

Over the past two years, we have invested considerable effort in building relationships with some of the leading technology developers, adding a range of technologies, methods and procedures that can significantly benefit our clients via accelerated development programs and improved process economics. Our powerful partnerships include BIA Separations, Invitrogen PD Direct, Oxford Expression Technologies, Millipore and Selexis.



Chapter 4: Key Milestones

Since opening the doors of our UK facility in 2006, we have completed well over eighty commercial projects and our customer base continues to grow as our established track record and reputation attracts an increasing number of new partners and friends throughout the world.

Within the past month alone we have signed a significant

multi-million £ contract with a world leading pharmaceutical company for the development and manufacture of a critically important vaccine product.

We are successful because of the calibre of our people. As part of a major pharma business, with a growing client base and expanding project portfolio Eden recruits the very best. Please visit our current job

2004-£10m
seed capital raised
by Stephens Inc.

2007-Successful first
MHRA (EMA)
Inspection for IMPs

2009-2nd successful
MHRA (EMA)
Inspection for IMPs

2010-Acquisition
by Watson
Pharmaceuticals, Inc.
(NYSE: WPI)

2010

2006-Eden
facility on-line

2008-Eden
Biodesign, Inc.
incorporated & office
established. Collaboration
agreements signed to aid market
penetration & service expansion.

2009-Type V DMF
in submission

2010-Employing
90 staff

vacancies page if you believe
you possess the personality
and skills to contribute to Eden
Biodesign's continued future
growth and success.





Chapter 5: About Eden Biodesign

As an established international biopharmaceutical development and manufacturing services provider, Eden Biodesign understands the required technical and regulatory issues involved in accelerating novel vaccine products into and through clinical development.

Eden Biodesign offers the most scientifically advanced development and manufacturing services to biotech clients across Europe, the USA, Asia, Africa and Australia. We understand the

challenges facing vaccine developers worldwide. And we begin with the end in mind, helping you develop valuable biopharmaceutical medicines through the application of good science, right from day one.

Clients turn to Eden Biodesign for:

Consultancy: Eden provides global CMC support, regulatory services, training, strategic insights and clinical logistics support.



Process Design &

Development: Eden specializes in helping our clients develop well-defined, robust, scalable and reproducible processes, that are both commercially viable and regulatory compliant.

cGMP Manufacturing

Expertise: Eden offers cGMP cell banking services and capabilities for all major types of production technologies, including microbial, mammalian and viral.

World Class Facilities: Our

world-class facilities provide the full range of services required to take novel biopharmaceuticals and vaccines from proof of concept through cGMP manufacturing for clinical trials.



Eden Biodesign Headquarters

Eden Biodesign Ltd.

NBC

Estuary Banks

Estuary Commerce Park

Speke Road

Liverpool, UKL24 8RB

In the U.S.


Eden Biodesign, Inc.

2530 Meridian Parkway, Suite 300

Durham

NC 27713

USA



Visit Our Website
www.edenbiodesign.com